Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Galectin Therapeutic (GALT)

Galectin Therapeutic (GALT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 183,742
  • Shares Outstanding, K 56,886
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,900 K
  • 60-Month Beta 3.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.05 +1.80%
on 11/18/19
4.50 -31.00%
on 11/11/19
-0.71 (-18.72%)
since 10/18/19
3-Month
2.94 +5.61%
on 08/23/19
4.50 -31.00%
on 11/11/19
-0.30 (-8.68%)
since 08/16/19
52-Week
2.94 +5.61%
on 08/23/19
6.06 -48.76%
on 02/21/19
-1.95 (-38.64%)
since 11/16/18

Most Recent Stories

More News
Galectin Therapeutics Reports Q3 2019 Financial Results

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended...

GALT : 3.12 (-3.41%)
Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis

Today, Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration agreement with Siemens Healthineers, a global leader in...

SIEGY : 63.3400 (-0.27%)
GALT : 3.12 (-3.41%)
Additional Ad Hoc Analysis of ELF Data from Galectin Therapeutics NASH-CX Phase 2 Clinical Trial to be Highlighted in Poster Presentation at the 2019 AASLD Liver Meeting

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based on results obtained in subsequent ad hoc analysis of...

GALT : 3.12 (-3.41%)
Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute announced today they have received notice of issuance of...

GALT : 3.12 (-3.41%)
Small Drug Stock Outlook: Innovation Holds the Key to Growth

Small Drug Stock Outlook: Innovation Holds the Key to Growth

ZTS : 118.89 (+0.82%)
VRCA : 14.10 (-4.21%)
LCI : 9.03 (-1.20%)
GALT : 3.12 (-3.41%)
New Strong Buy Stocks for August 27th

New Strong Buy Stocks for August 27th

LZB : 37.10 (+0.95%)
IBA : 50.65 (-1.09%)
HIBB : 26.69 (+2.69%)
GALT : 3.12 (-3.41%)
DBD : 7.85 (-3.56%)
FibroGen (FGEN) Catches Eye: Stock Jumps 7.4%

FibroGen (FGEN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

FGEN : 36.63 (-0.97%)
GALT : 3.12 (-3.41%)
Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended...

GALT : 3.12 (-3.41%)
Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View

Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.

GALT : 3.12 (-3.41%)
PTLA : 27.80 (+2.17%)
BHC : 28.42 (-0.21%)
ETON : 5.71 (-2.56%)
Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y

Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.

MRK : 84.16 (-0.87%)
ENDP : 4.44 (-1.99%)
GALT : 3.12 (-3.41%)
PTLA : 27.80 (+2.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade GALT with:

Business Summary

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring...

See More

Key Turning Points

2nd Resistance Point 3.49
1st Resistance Point 3.36
Last Price 3.12
1st Support Level 3.13
2nd Support Level 3.03

See More

52-Week High 6.06
Fibonacci 61.8% 4.87
Fibonacci 50% 4.50
Fibonacci 38.2% 4.13
Last Price 3.12
52-Week Low 2.94

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar